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We present a theory for the laboratory and epidemiological data for incubation times in infectious
prion diseases. The central feature of our model is that slow growth of misfolded protein-aggregates
from small initial seeds controls the ‘latent’ or ‘lag’ phase, whereas aggregate-fissioning and sub-
sequent spreading leads to an exponential growth or doubling phase. Such a general framework
can account for many features of prion diseases including the striking reproducibility of incubation
times when high doses are inoculated into lab animals. Furthermore, we explore the importance of
aggregate morphology in determining the statistics of the incubation time. Broad incubation time
distributions arise for low infectious dose, while our calculated distributions narrow to sharply de-
fined onset times with increased dose. We use our distributions to obtain a fit for the experimental
dose-incubation curves for distinct strains of scrapie and show how features of the dose-incubation
curve, specifically (a) the logarithmic dose-dependence at high dose and (b) deviations from log-
arithmic behavior at low dose can be explained within our model. By fitting the experimental
dose-incubation curves, we quantify our model parameters and make testable predictions for exper-
iments which measure the time-course of infectivity. We apply our model to analysis of data from
BSE epidemiology, iatrogenic CJD infections, and vCJD infections; these data are consistent with
incubation times dominated by slow aggregation from a few seeds which are tens of nanometers
in size. Within the model, small mammals derive shorter incubation times from much more rapid
protein attachment rates which we suggest to arise from higher PrPc concentrations that might be
metabolically controlled. Further, based upon our analysis we suggest that vCJD incubation times
are likely to be at the low end of previous estimates.
I. INTRODUCTION
Understanding the factors which regulate the incuba-
tion times for infectious prion diseases is important for
assessing the risk of illness after potential exposure as
well as for developing treatments which can delay disease
onset. There are several striking aspects to prion disease
incubation, which are not well understood: (i) The in-
cubation times can run into years and decades [1], and
yet, at the laboratory scale have been found to be highly
reproducible. In fact, the reproducibility of incubation
times with dose has been used as an independent mea-
sure of infectivity titre [2,3]. (ii) There seem to be distinct
stages for the disease incubation after intracerebral inoc-
ulation: (a) Following rapid initial clearance, there is a
‘lag’ phase (also termed ‘zero’ phase [4,8]) during which
there is little or no infectivity, and (b) an exponential
growth or doubling phase, during which the infectivity
increases exponentially with a well-defined doubling pe-
riod [5–7]. Understanding the lag-phase is clearly impor-
tant as any treatment strategy is more likely to succeed
before the exponential growth phase takes over. (iii) As
the dose of infection is increased in the laboratory, the
incubation times become sharply defined and saturate to
a dose independent value, but as the dose is reduced a
broad distribution and a logarithmic dose dependence re-
sults [9]. Such a broad distribution has also been found in
epidemiological studies of Bovine Spongioform Enceph-
elopathy (BSE) in England [10,11]. (iv) For infection
across species, there is a ‘species barrier’ and the first
passage takes considerably longer to incubate than sub-
sequent passages [12,13]. (v) While prion aggregation has
been observed in vitro, the aggregates are neuro-toxic but
not infectious [14]. These are the issues which motivate
our study.
The purpose of this paper is to test the extent to which
a purely physico-chemical model can capture the main re-
producible features of prion disease incubation. In par-
ticular, we emphasize the importance of the aggregate
morphology in determining the statistics of incubation
times. Our basic hypothesis is that the ‘lag phase’ is de-
termined by growth of misfolded protein-aggregates from
initial small seeds (acquired through infection) to a typi-
cal ‘fissioning dimension’, whereas subsequent aggregate-
fissioning and spreading leads to exponential growth and
the doubling phase. For a single seed, the lag phase devel-
ops a broad but well defined distribution, which we can
calculate via a microscopic statistical model. Thus, when
the infection is very dilute, there is a broad distribution
of incubation times. At higher doses of infection, self-
averaging due to independent growth from many seeds
leads to sharply defined incubation times. The dose de-
pendence and its saturation, as well as the ratio of lag
time to doubling time depends on the morphology of the
aggregates, i.e., whether one has linear fibrils or compact
higher-dimensional aggregates. In this sense, details of
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incubation time distributions provide an indirect means
to infer early growth morphologies. Alternative theoret-
ical models which deal with the above issues have also
been developed in the literature. [15–18,20,19,21]
The extent to which such a model explains the experi-
mental phenomenology would help address the following
questions: (i) Are the incubation times dominated by the
nucleation and growth of misfolded protein aggregates?.
(ii) Are the two phases of prion disease incubation, the
lag phase and the exponential growth phase, controlled by
the same process i.e. aggregation of misfolded proteins?
(iii) Assuming that aggregate growth controls the incuba-
tion time scales, we are led to ask: What is the aggregate
morphology during early growth and how does it influ-
ence the dose incubation curves (iv) Does current data
inform us about the characteristic size of the aggregates?
(v) What are the practical epidemiological impacts from
our model incubation time distributions? Can we use the
model to constrain estimates of the number of infections
of vCJD for example?
Employing statistical simulations of prion aggregation
(based upon cellular automata rules) we argue here that
several features of prion disease can be explained by ex-
ploring the statistics of the two phases of the disease in-
cubation. Within our model, we show that compact two-
dimensional aggregates can provide the observed broad
distribution of incubation times for dilute doses and at
the same time account for the typical large difference
between lag time and doubling time. We present ana-
lytic calculations which provide a functional form for the
distribution that can be used in further epidemiological
studies, and we use these results to infer the dose depen-
dence of the incubation time. Furthermore, our analysis
shows how the dose-incubation curve can be related to
experimental measurements of the time-course of infec-
tivity and in particular, testable predictions can be made
using our model for the dose dependence of the lag phase.
Finally, we apply our model to epidemiological data for
BSE (mad cow disease), iatrogenic CJD infections asso-
ciated with dura mater transplants, and a vCJD cluster
from the United Kingdom, from which we conclude that
in all three cases the incubation time is dominated by
slow aggregation from a few small (tens of nanometer
scale) starting seeds. This size scale is comparable to
small animals, but the estimated attachment rates are
slower by an order of magnitude or more. We argue that
the incubation time for vCJD is likely to be at the low end
of previous estimates, implying an infectious toll in the
hundreds rather than hundreds of thousands. We spec-
ulate that the differing attachment rate among species
is regulated by the PrPc concentration which in turn is
metabolically controlled.
We organize our paper as follows: Section II discusses
a model incubation time distribution, which illustrates
how our basic picture relates to dose incubation curves
in prion diseases. Sections III-V deal with microscopic
models related to protein misfolding, aggregation and fis-
sioning. In Sections VI, VII, and VIII, we come back to
the dose incubation curves, connections to epidemiologi-
cal data and the disease phenomenology and discuss them
in context of our models and present our conclusions.
II. A MODEL DISTRIBUTION AND DOSE
INCUBATION CURVES
We first illustrate the ‘bare bones’ of our proposed pic-
ture for prion disease incubation by using a model distri-
bution, where calculations can be done analytically. As
mentioned in the previous section, the lag phase corre-
sponds to aggregation of misfolded prions from the initial
seed upto a ‘fissioning size’. This is a stochastic process
and correspondingly there will be a distribution of aggre-
gation times. Subsequent to this aggregation, we assume
(based upon experimental observations) that the num-
ber of seeds increases exponentially with a well defined
doubling time (t2). This exponential growth continues
until the number of seeds reaches a critical value which
signals the onset of clinical symptoms and the end of the
incubation period.
In this section, we assume the distribution of aggrega-
tion times from a single seed, P (t), to be given by
P (t) = 0 t < t0 (1)
=
1
n1t2
t0 < t < t0 + n1t2 (2)
= 0 t > t0 + n1t2 (3)
Here t0 and n1 are the parameters for the distribution.
It has a sharp onset at time t0 and its width is taken
to be some multiple (n1) of the doubling time t2. When
there are many seeds present, each initial seed will start
fissioning into two new seeds after an aggregation time
according to the above distribution. We will assume that
once a seed has fissioned once, it continues to fission or
effectively double every t2 time steps, which is indepen-
dent of the above distribution. The microscopic basis for
this assumption will be explained in section V. The incu-
bation time is given by the mean time taken for a given
initial number of seeds (Di) to reach a critical number
(Df ) following the above processes.
The dose dependence of the the incubation time is cal-
culated through the following steps:
1) First we calculate the mean ‘first arrival’ time i.e.
the mean time taken for the first aggregate fissioning
event. Let the cumulative probability for the ‘first ar-
rival’ time for Di seeds be given by F
(Di)(t). Since each
seed grows independently, this can be related to the cu-
mulative probability for the ‘first arrival’ time for a single
seed via the relation
F (Di)(t) = 1− (1 − F (1)(t))Di (4)
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The mean first arrival time t1 is given by solving
F (Di)(t1) =
1
2 . For the simple probability distribu-
tion discussed above, the mean first arrival time is well-
approximated by the expression
tm(Di) = t0 +
n1
2Di
td (5)
2) We now proceed to calculate the time spent in the
doubling phase, i.e., the time taken till the number of
seeds reaches Df . All the aggregates formed after fis-
sioning are assumed to further fission in time t2. Besides
these, initial seeds continue to ‘arrive’, i.e., aggregate to
the fissioning size and thus join the number seeds that
are doubling. Let the number of such seeds ‘arriving’ in
the time interval m t2 < t < (m + 1) t2 be given by
α(m)D. Then, α(m) is given by
α(m) = F (1)((m+ 1)t2)− F
(1)(mt2) (6)
3) For our model distribution, the above equation can
now be used to calculate the mean incubation time, which
is approximately given by
ti = t0 +
n1
2Di
t2 + [log2(Df )− log2(1 +
Di
n1
)]t2 (7)
The above equation gives the dose-dependence of the
incubation time for the model distribution. It should
be noted that this expression already explains several
generic features seen in experimental dose-incubation
curves (DICs) and in the microscopic models we present
in later sections. These are: 1) logarithmic dose-
dependence at high doses and 2) deviations from loga-
rithmic behavior at low doses. From the above expression
for the incubation time, it can be seen that the dominant
contribution to the incubation time at high Di comes
from the ‘doubling’ phase which gives a logarithmic dose-
dependence. However at low doses (D ≤ n1), the time
spent in the doubling phase does not change appreciably
with dose. Instead, the variation in the incubation time
comes from the dose-dependence of the the ‘first arrival’
time i.e. the lag phase time. This is reflected as a devi-
ation from the logarithmic behavior in the DIC which is
seen in experimental DICs [22]. Our model thus makes
the testable prediction that deviations from logarithmic
behavior in the DIC should correspond to increases in
the lag phase.
We now proceed to develop microscopic models for the
initial aggregation process. The next section discusses
the cellular automata approach to this problem.
III. CELLULAR AUTOMATA SIMULATIONS
Theoretical modeling of incubation times [16,15,23]
starting at the molecular-level is all but impossible with
a twenty order of magnitude span between molecular mo-
tion time scales and those of disease onset. On the other
hand, kinetic theory allows one to model long-time pro-
cesses but ignores short distance spatial fluctuations, im-
portant in nucleation and growth. We have developed
a lattice-based protein-level cellular-automata approach,
which bridges these two methodologies [24]. Previously,
we used it to calculate aggregation-time distributions,
which compared favorably with the incubation-times in-
ferred from BSE data [10,11]. We also showed that play-
ing with the rules in such simple models can be a “cheap”
way to suggest, constrain and guide treatment protocols.
Our models consist of dilute concentrations of pro-
teins diffusing on the lattice and interconverting between
their properly folded state (PrPc) and the misfolded state
(PrPSc) [25]. Our key assumption is that the conforma-
tional state of a protein depends on the amount of water
around it. A monomer isolated from others (surrounded
by the omnipresent water) stays in its properly folded
state. However, when proteins are surrounded by other
proteins, thus excluding water from parts of their neigh-
borhood, they can change conformations and go into a
misfolded state (involving β sheet bonding). A key pa-
rameter of our model is the coordination, qc, at which
the misfolded conformation PrPSc becomes stable. Only
misfolded monomers may remain stably in a cluster, pos-
sibly breaking away from a cluster when they fold back
into the PrPc form.
Assuming aggregation happens on the cell-surface, we
choose a 2d hexagonal lattice. There is strong evidence
that the local coordination environment of the sphin-
golipids to which the prion proteins attach is, in fact,
hexagonal [26]. The lattice structure and the detailed
protein motion are not crucial in our model. At each
time step, proteins can move randomly by at most a unit
lattice spacing. The magnitude of the time-step is set by
the time for a single monomer to misfold. It is implicitly
assumed that proteins co-adsorb with each other followed
either by a conversion in shape or separation. It is this
conversion process which sets the unit of time.
By playing with the cellular automata rules it is pos-
sible to get different aggregate morphologies and aggre-
gation time distributions. First, we consider the case
where proteins are isotropic objects. We have performed
a large number of runs at values of qc = 1, 2, and 3, with
different monomer concentrations (held fixed during the
simulation). The aggregation time is defined as the time
required to grow from initial seed of size Ai to a final
size A. The lower coordination rules effectively remove
the nucleation barrier, leading to frequent nucleation of
new clusters. Typical aggregate configurations (and sta-
ble seeds) are shown in Fig. 1.
From these studies, we see that lowering the critical
coordination provides too rapid a growth for prion ag-
gregates, and with no nucleation barrier at these con-
centrations. In contrast, for qc = 3, the aggregation is
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very slow and it is characterized by a broad incubation
time distribution, with a clear separation in time-scales
for seeded and unseeded (i.e. infectious and sporadic)
cases.
We can also obtain one dimensional fibril growth by
considering the proteins to be anisotropic. For example,
on a square lattice, we can get fibrils by: (i) identifying a
preferred bonding face to our simple point proteins, now
made into squares. (ii) We choose a critical coordina-
tion of 2. (iii) We make edge bonding of proteins with
adjacent preferred faces to be quite strong under coordi-
nation q=1 (i.e., the conversion probability is higher than
50%), and somewhat less strong for face to face meeting
of proteins. We assume zero conversion probabilities for
all other faces. By choosing three kinds of faces with ap-
propriate rules, we can obtain equivalent results on the
hexagonal lattice. These rules assure fibril growth which
is dimer dominated (see Fig. 1).
IV. STOCHASTIC ANALYSIS OF
AGGREGATION
In the low concentration limit, the aggregation results
from a sequential addition of proteins to the initial seed.
However, addition of monomers is not always stable.
Given the rules, various stages of the aggregate size and
shape require a pair of proteins (a dimer) to arrive simul-
taneously, in order to attach in a stable manner. Thus,
the entire process can be approximated by one of stochas-
tic sequential addition of monomer and dimer units. As
the concentration, c, goes to zero, the monomer addition
rate is proportional to c, whereas the dimer addition rate
is proportional to c2, and thus the growth will involve a
minimum number of dimers and these will provide the
dominant contribution to the growth times.
The growth to a final size A from an initial size Ai
involves sequential addition of n units. The probability
for the successive additions at intervals t1, t2, . . ., tn is
P (t1, t2, . . . , tn) =
n∏
j=1
pje
−pjtj , (8)
where the rate for the jth unit, pj , depends on the geom-
etry of the aggregate and the kind of unit (monomer or
dimer) to be added. Hence, the probability distribution
associated with the total growth time is
P (t) =
∫ ∞
0
dt1 . . .
∫ ∞
0
dtn
n∏
j=1
pje
−pjtδ(t−
n∑
i=1
ti). (9)
This integral can be evaluated by standard methods for
arbitrary pi. We note the answers for two cases:
1) The attachment probabilities are identical for each
unit i.e pj = p for all j. In this case the probability
distribution is the Gamma distribution:
P (t) =
p(pt)n−1
(n− 1)!
e−pt (10)
2) The rate, pj = p + jp
′, increases linearly with j. In
this case we obtain the Beta distribution in e−t [27]:
P (t) = Ae−(p+p
′)t(1− e−p
′t)n−1 (11)
In 1d fibril growth, dimers are attached one by one with
the area available for attachment of dimers staying con-
stant, and thus Eq. 10 applies. For 2d compact growth,
slow dimer attachments have to be combined with rapid
filling up of rows by monomers. In the low concentration
limit, the rate is limited by dimer attachment probabil-
ities which increase linearly with the number of dimers
already attached, thus leading to Eq. 11.
At finite concentrations, the monomer attachment
times can no longer be neglected, and a more accurate
treatment of the time scales in the 2d case requires a con-
volution of probabilities for monomer attachment times
with those for dimer attachment times. The geometrical
counting of number of monomers and number of dimers
needed to grow to the desired size is straightforward and
can be used to develop accurate fits to the numerical data
(See Figure 2 A).
An important aspect of our 2d model is the asymptotic
compression of the distributions at low concentrations.
The initial stage of the growth is extremely slow and the
process speeds up significantly as the aggregate grows.
Thus, the mean aggregation time, tm(1) to go from an
initial seed Ai to a final size A can be much larger than
the typical aggregate-doubling time t2 to go from size
A/2 to A. Fig. 3 shows the ratio t2(1)/tm(1) for different
concentrations and different final sizes A. The crossover
to monomer dominated behavior (t2/tm(1) ≈
1
2 ) is indi-
cated at the highest concentration whereas at low con-
centrations this ratio can be much smaller.
V. AGGREGATE-FISSIONING
Fissioning of aggregates leads to exponential growth as
the fission products provide seeds for the next round of
aggregation. In this subsection, we consider two mech-
anistic models of the fission process associated with ei-
ther proteolytic cleavage of aggregates or mechanically
induced breakage. We acknowledge that other models
are possible.
We assume that the fission time is small compared to
the aggregation time, and thus work in the limit of ‘in-
stantaneous fission’ in which breakage of an aggregate
happens much more rapidly than aggregation. This im-
plies a narrow distribution of fission sizes peaked, say,
at aggregate size A, and in this limit our results are
expected to be independent of the width of the fission
distribution.
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We consider two extreme limiting models of fission:
(i)Mechanical. In this case, once the aggregate reaches
fission size A, it splits into two fragments of equal size
A/2. This should approximately describe the situation
in which aggregate size is limited by nerve cell curvature
(e.g., aggregation favors flat planar or linear structures,
but the curvature of the neuron tends favors curved struc-
tures). (ii) Physiological. In this case, the aggregate can
break into all smaller lengths at the fission scale. This
mimics the outcome of protease attack for which there is
no obvious preferred site for breakage.
Taking a fixed background concentration of monomers,
which should be reasonable for at least short times in the
disease. The kinetic equation for the time evolution of
aggregates with size n (measuring the number of dimers
present) and concentration [an] is, for n < A,
d[an]
dt
= pn−1[an−1]− pn[an] + pf,n[aA] (12)
and, for n = A,
d[aA]
dt
= pA−1[aA−1]− pf,0[aA] . (13)
Here, for 1d aggregation pn = p0, while for the 2d aggre-
gation specified by our critical coordination three rules
discussed in Sec. III, pn = p + np
′. For mechanical
fission, pf,n = 2pf0δn,A/2, while for the physiological fis-
sion, pf,n = 2pf0/(A − 1). The instantaneous fission
assumption requires pf,0 >> p, p
′.
We can identify the doubling time from Eqns. 12 and
13 by the following procedure: (i) Laplace transform the
set of coupled equations to obtain a matrix equation in
transform space; (ii) identify the largest positive eigen-
value of the Laplace matrix. In all cases, we find but
one positive eigenvalue. We have systematically varied
the fission size A and studied the dependence of the ex-
ponential growth rate upon fission time. For fibrils, the
mean time to aggregate to size A is tm ≈ A/p, while
for the 2d aggregates, the mean aggregation time goes as
tm ≈ ln(A)/p
′. In the one dimensional case, we find that
for large A, the doubling time t2 tends to 0.5(0.43)tm
for mechanical(physiological) fission. Hence, there is but
a factor of two difference between the aggregation time
and the doubling time. Since the numerical difference
between mechanical and physiological fission is not sub-
stantial, we have examined only the mechanical fission
model for the 2d aggregate. In this case, we find that the
largest eigenvalue of the Laplace matrix goes as ≃ 0.4/p
independent of A, while the aggregation time scales as
ln(A)/p′. Hence, for sufficiently large A it is possible to
make t2/tm << 1.
These results have the attractive feature of linking the
aggregation time, which we associate with the lag phase,
to the doubling time in fission. However, we acknowledge
that other processes may properly describe fission. In
particular, we cannot rule out continuous fissioning of
fragments off of large aggregates which may lead to a very
different result provided the fission rate is comparable to
growth rates.
VI. DOSE-INCUBATION CURVE
In this section, we will look at the total incubation
time and how it varies as a function of the inoculated
dose using the aggregation-time distributions derived in
the previous sections, and explore the extent to which it
provides a quantitative description of experimental dose
incubation curves. As discussed before, a key advantage
of the 2D growth models is that, with a suitable fissioning
scenario, they lead to lag times much larger than dou-
bling times. This is difficult to accomplish with the 1D
growth models. However, in this section we will assume
that the doubling time is an independent free parameter.
This allows us to fit the experimental dose incubation
curves by both 1D and 2D models. The constraints on
relative values of lag times and doubling times will be
brought up in our discussions in the next section.
We now proceed to calculate the incubation time as a
function of inoculated dose within our model for both 1d
and 2d aggregation models and compare with laboratory
data. Consider first the DIC of the 263K hamster scrapie
strain. Kimberlin et al [28] have determined the DIC
along with independent measurements of the doubling
time t2 and the final infectivity for this strain. The dou-
bling time t2 can also be inferred from the DIC in the re-
gion where it shows a logarithmic dose-dependence. Be-
sides this experimental data, we need to know the clear-
ance ratio ri which gives the percentage of the number of
infectious seeds in a given inoculum which are removed by
rapid initial clearance. Let us illustrate this for the case
of 1 LD50 unit : in our model this corresponds to having
a 50% probability of attaching a single infectious seed.
Correspondingly the initial inoculum has to contain, on
average, 50100−ri seeds (for ri > 50%, typical values from
experiment are ri ∼ 99% [5]). We treat ri as a param-
eter in our model to be determined by fitting the DIC.
Using this, in conjunction with our results for the ag-
gregation time distributions, we can generate theoretical
DICs using the method outlined in Section II.
For a fixed aggregation size A, probability of attach-
ment p and infectivity ratio ri, we then calculate the
mean-square deviation (S2) (normalized by the experi-
mental error estimates for each data point) between the
theoretical and experimental DICs. Minimizing S2 gives
us the optimal parameters, p and A, for the particular
strain for a given value of ri within our model.
We consider first the DIC for the 263K hamster scrapie
strain. In carrying out the fitting, we have ignored the
results at the highest doses since in this limit we are ap-
proaching the saturation of the incubation time. For our
5
2d growth model, we get a good fit to the experimental
data as indicated in Fig. 4a. The optimal parameters in
this case are A = 16 (with Ai = 10), p = 0.025 day
−1
and ri = 0 (which seems unphysical) for which S
2 ∼ 0.07.
For a more realistic value of ri ∼ 88% we get A = 16,
p = 0.16 day−1 with S2 ∼ 1.14. From the fitting, one
can see that the clearance ratio ri cannot be much greater
than ri ∼ 88% due to the constraints imposed by the ex-
perimental incubation and doubling times. It should be
noted furthermore, that the above procedure does not
uniquely determine these parameters since comparably
good fits are obtained for higher values of A by corre-
spondingly adjusting p. For the 1-d growth model, we
also get a good fit with S2 ∼ 0.35 forA = 8 (with Ai = 4)
and p = 0.11 day−1.
One of the unusual features of the 263K scrapie strain
in hamsters is that at high doses the lag-time is negligi-
bly small. This feature is clearly seen in the time-course
measurements [28] of infectivity and also accords with
the theoretical best-fit results described above. In order
to test our procedure for a more representative strain we
have also obtained a fit for the experimental DIC for the
ME7 strain in C57Bl mice [29]. The results obtained by
using our 2d growth model are shown in Fig. 4b. In this
case, the theoretical fit is not as good as that obtained
for the 263K strain; the optimal parameters correspond
to A = 140, p = 0.033 day−1 for ri = 99 which gives
S2 ∼ 3.75. A comparably good fit was obtained by us-
ing the 1d growth model with the optimal parameters
A = 40, p = 0.23 day−1 for ri = 99 which gave S
2 ∼ 5.02.
However in contrast with the 263K strain, the theoreti-
cal results for the ME7 strain give rise to a significant lag
time of ∼ 50 days for the highest dose inoculated. This
is a testable prediction for time-course measurements of
infectivity for the Me7 strain in C57Bl mice.
Finally, we have used the above procedure to ana-
lyze the Sc237 scrapie strain in hamsters. In many re-
spects, this strain is similar to the 263K scrapie strain
in hamsters, however an analysis of the respective DICs
reveals some significant differences. Based on the theo-
retical best-fit formula for the DIC [3], we can estimate
a doubling time t2 for the Sc237 strain to be ∼ 2.1 days
whereas the doubling time for the 263K strain is ∼ 3.9
days. This difference is also reflected in our theoretical
best fit DIC curve for this strain which, for ri = 99, is
given by the parameters A = 80 p = 0.052 day−1. For
our 1d model the corresponding values are A = 62, p =
0.35 day−1. Note that the experimental error estimates
were not available for dose-incubation data for this strain,
so we assumed them to be the same as that for the 263K
strain in determining the best fit. Using the above fits,
we see that the theoretical prediction for the mean lag-
time for an inoculated dose of 1 LD50 unit is ∼ 50 days.
This value seems to be in good agreement with the ex-
perimental results for low dose inoculations for this strain
[3].
The key results from our fitting (using the 2d growth
model) are summarized in Table I. Based on the above
results, we conclude that while our model accounts for
the features of the DIC and gives a good fit to the ex-
perimental data, the latter cannot be used to distinguish
between the 1d and 2d growth morphologies or to ascer-
tain the model parameters conclusively. However despite
the ambiguity in the model parameters, there are some
robust predictions we can make after fitting the DICs.
We find that the experimental DIC, in conjunction with
our model, can be used to make predictions for the time-
course of infectivity: in particular we can predict the
lag-time as a function of dose. While the duration of
the lag-time that we calculate does depend on the clear-
ance ratio ri, we note that the trend is that increasing
ri reduces the lag-time. Thus by measuring the lag-time
at high doses we can determine the parameter ri in our
model, which then yields testable predictions for the lag-
time at low doses. In the case of the the Sc237 scrapie
strain in hamsters, our calculated lag-time at low dose
agrees well with experimental results for the same. For
the other strains, the predictions for the lag-time at low
dose are a key testable prediction of our model.
VII. CONNECTION TO EPIDEMIOLOGICAL
DATA
We have found no dose incubation time data available
for large mammals in the literature, so to gain insight we
have analyzed epidemiological data for BSE in cattle [11],
a tabulation of incubation times from iatrogenic CJD as-
sociated with dura mater transplants [38], and the cluster
of five victims of vCJD from the village of Queniborough
in the United Kingdom [39–41]. The goal is to produce
approximate estimates of aggregate size and growth time
scales for comparison to the small mammal data, and,
potentially, to guide future epidemiological and public
health studies.
In brief, our assumptions and methods are as follows:
1) Model Distributions We apply only the 2d model in
the dilute dose limit (suitable for digested prions); com-
parable quality fits can be obtained from the 1d model,
but the estimated t2/tm ratio consistently and strongly
violates our mechanistic model result from Sec. V, while
the bound for the 2d case is satisfied.
2) Number of Doublings. For mice and hamsters, with
1g brains, 30 doublings to incubation is typical. Given
that the mean cattle brain is 500g, and the mean human
brain 1500g, we take n2 = 40 doublings from infection to
incubation for cattle and humans.
3) BSE fits. Ref. [11] provides a candidate incuba-
tion time distribution which best fits the epidemic time
course, and yields a mean incubation time < t >=5 years
and standard deviation of 1.3 years. The width fixes
p′ uniquely for given n, l = 1 + p′/p, with p′ weakly
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dependent upon n. We readily calculate tm(n, l, p
′)≈
(ψ(n+l)−ψ(l))/p′, and we take the difference < t > −tm
to be n2t2, the length of the exponential growth phase.
With a minimum t2=5 days typical for hamsters and mice
(see Table II), the maximum n value can be be found at
given l. For small aggregates, n = 6 is taken to be a
plausible minimum value which bounds t2 above as 15
days. The results for l = 2, 10 are summarized in Table
II. Importantly, we find the maximum aggregate size at
fission to be of order 80-100 monomers, approximately
independent of l for 2 ≤ l ≤ 10.
4) Fits to iatrogenic CJD data. The data of Ref. [38]
sharply constrain the size of the aggregate at fission,
since the ratio of standard deviation (≃ 3 years) to mean
(≃ 5.8 years) rules out n > 4 for all l = 1+p′/p values. To
fit the data we perform the following procedure: a) We
produce a parameter free estimate of tm by multiplying
σ by the ratio of tm/σ for a given choice of n, l; this sub-
tracted from < t > yields the estimated doubling phase
period (and t2, assuming n2 = 40 as above). (b) Using
the estimated value of n2t2, we produce a one parameter
fit in p′ to the cumulative distribution F (1)(t− n2t2) for
the given n, l choice. We find for n = 3, we can consis-
tently fit for all l, while for n = 4, comparable quality fits
are obtained for l = 2, 3, but for l ≥ 4 n = 4 is no longer
a viable choice. The resulting robust estimates of incu-
bation parameters are t2 = 5.4± 0.4 years, σ = 3.2± 0.2
years, and t2 = 7± 1 days. The attachment rates p
′ vary
systematically with l, but are at most 0.22±0.042/year.
(Error bars reflect 95% confidence intervals.)
5) Fits to Queniborough vCJD incubation time data. For
vCJD, we have extracted an estimated onset time dis-
tribution from the Queniborough cluster, taken as incu-
bation times, from the available scientific and journal-
istic literature [39–41]. We assume that this is a single
dose event, in the low dose limit. We determine the es-
timated mean < t > from the five data points to be
Feb., 1998. Using non-linear leas squares analysis, we
fit the cluster data to the cumulative beta distribution
F (1)(t− < t > +tm(n, l, p
′)), placing points at half steps
of probability increment. We also estimated the upper
and lower bounds to p′ corresponding to 95% confidence,
which yields a corresponding range for tm, σ. Unlike
the iatrogenic CJD and BSE data, the overall incuba-
tion time is unknown, which prohibits an estimate of t2.
We thus take a reasonable estimate for the maximum
doubling time at tmax2 ≤ 30 days. Using the minimum
estimate of 9.0 years for the incubation time from epi-
demiological studies [32], we thus estimate a minimum
lag time of tminm = t
min
inc − n2t
max
2 = 5.7 years. The mini-
mum aggregate size at fission which can exceed this tminm
value at the upper 95% confidence limit is n = 4, l = 2
(16 monomers). We can take the upper aggregation size
limit from BSE as a reasonable bound (n = 20, l = 2 or
n = 10, l = 10 giving 80 monomers). We summarize our
results in Table III, for two values of l. We stress that our
results here are at best a crude guide to expected model
fits since: (1) there are only five data points to fit to and
several model parameters, (2) the infection is likely to be
characterized by slow heterologous protein attachment for
short times and more rapid homologous attachment for
long times, while we assume a single effective attachment
probability, and (3) there is no guarantee that the pos-
tulated single event was in the low dose limit.
Given the simplicity of our model and the assump-
tions made for fitting, we shall emphasize the most ro-
bust results of our analysis. Our results are summarized
in Tables II (BSE), III (vCJD). We find several robust
features:(i) For BSE, iatrogenic CJD, and vCJD, we find
that a wide range of l produce comparable fits, corre-
sponding to a different starting seed size. We have thus
quoted values from l = 2 and l = 10, the former rep-
resenting nearly minimal seed sizes, the latter maximal
plausible ones. (ii) In all three cases, the standard de-
viation of the incubation time distribution is large (1.2
years for BSE, vCJD, and 3.2 years for iatrogenic CJD),
supporting the assumption of small dose. (ii) The at-
tachment rates are all comparable (BSE: 0.6/yr; iatro-
genic CJD: ≤ 0.2/year; vCJD: ≤ 0.66/yr) and are sig-
nificantly smaller than for the small mammal analysis
of the previous section (≥ 11/year from Table I). (iii)
For BSE and CJD, t2 is comparable to values for small
mammals (eg., ≤15 days for BSE, 8 days for iatrogenic
CJD). For all strains considered here with the exception
of 263K for hamsters, ratios of t2/tm are small. We shall
discuss the large t2 values for vCJD below. (iv) Aggre-
gate sizes are comparable for large and small mammals
(≤ 80− 100 monomers for BSE, for iatrogenic CJD with
l = 2, n = 3 we get 16 monomers, and for vCJD appar-
ently tens of monomers also), compared with 16-360 for
the small mammals of Table I. Hence in each case, given
a 2 nm characteristic protein size, the length scale is of
order tens of nanometers. (If the aggregating entities are
in fact oligomers as suggested by Ref. [26], we only double
the length scale.)
Hence, our analysis strongly suggests interspecies vari-
ation in incubation times is dominated by tm, given given
similar doubling times and aggregate sizes. In our model,
variation in tm is governed by p
′, which then suggests a
significantly higher homeostatic monomer concentration
in small mammals compared to large ones, a point we
discuss further below.
Our fitting of the Queniborough data also suggests that
long (≥ 20 years) incubation times for vCJD are implau-
sible. The maximum tm value found (at the upper 95%
confidence limit) for n = l = 10 is 9.3 years; even with
the extreme t2 = 30 day value, this gives a 12 year in-
cubation time. We note that the most probable (best
fit) p′ values yield larger and implausible t2 values for
the minimum epidemiological estimate of the incubation
time. To the extent our model is applicable, this implies
7
9 years likely overestimates the incubation period. In
consequence, in conjunction with epidemiological analy-
ses, our work suggest that the number of vCJD infections
is likely to number in the hundreds.
VIII. DISCUSSION
Recall that our basic hypothesis is that incubation
times are controlled by prion-aggregation around infec-
tious external seeds on the neuronal surface. Further-
more, in our calculations, the distribution of aggrega-
tion times arises from the stochastic growth process from
seeds of a given initial size. That only a narrow range
of seed sizes is relavant here maybe motivated by size-
sensitivity of (a) the blood-brain barrier (b) attachment
probability and (c) transportability of the seeds. The lag
phase corresponds to growth from initial seeds to a char-
acteristic fissioning dimension A, after which one gets
a multiplication in seeding-centers and an exponential
growth in infectivity.
That there is a long lag time despite external seeding
by intracerebral inoculation [5,8], and a doubling time
which is typically significantly shorter [5], both of which
become sharply defined at high doses, seems to be a gen-
eral feature of the prion diseases. Our 2d compact aggre-
gate model, with the assumptions of the preceding para-
graph, explains these facts. In particular, 2d compact ag-
gregation generates a broad distribution of aggregation
times for a single seed with a well defined sharp onset
time (t0) and mean aggregation time (tm(1)). With in-
creasing number of seeds (Di), the distribution of times
for the first seed to reach the typical fissioning size A
will narrow. Correspondingly the lag time, determined
by the first fissioning event, will become sharply defined
and concentrate at the onset time, which only weakly
depends upon Di.
The doubling time (t2) is defined by fissioning and
subsequent growth from size A/2 to A. Since growth
from different seeds is independent, self-averaging (‘law of
large numbers’) gives a sharply defined t2. Thus at high
doses both the lag time and doubling time are sharply de-
fined which accounts for one of the most striking features
of prion diseases: the reproducibility of incubation times
at high doses. Indeed, we can explain several features of
the dose-incubation curve. Notably, above a saturation
dose Ds, the incubation time does not decrease, while for
D < Ds, the incubation time varies as log(D), showing
deviations from the log only below a much smaller value
Dmin [2,17]. The total incubation time is the sum of the
lag time and ndt2, where nd is the number of doubling
steps. Assuming that the onset of clinical symptoms is
related to the damage of a fixed number of neurons [16],
the logarithmic dose dependence of the number of dou-
bling steps follows from the fact that number of seeds
grows exponentially in the fissioning stage. In the range
Dmin < D < Ds, the lag time does not change appre-
ciably with dose, thereby giving rise to the logarithmic
dose-dependence of the incubation time in this range. At
low doses (D < Dmin), the lag-time increases towards
tm(1) (the mean aggregation time for a single seed) giv-
ing rise to a broad distribution of incubation times and
the deviation from the logarithmic behavior in the DIC
which is observed experimentally. [22]
Furthermore, we note that in our mechanistic fission-
ing model, the doubling time (t2) is bounded above by
the time to grow from size A/2 to A. If the fission pro-
duces jagged fragments, these can be effectively filled by
monomers which will accelerate the subsequent growth
process. This is only possible for 2d compact aggregates
and not for 1d fibrils, for which the exposed ends will
always be limited to dimer growth. This possibility may
account for the effective ‘1/c’ dependence in the incuba-
tion time observed for transgenic hamsters with multiple
copies of the prion gene [30], noting that for hamsters the
doubling phase appears to dominate incubation [28].
A key difference between the 1d and 2d morphology
(shown in section IV) is that, within our model, in case
of the latter (i) the lag-time can be an order of magni-
tude larger than the doubling time. If the total time in
doubling-steps becomes large compared to the lag time,
the overall distribution will be relatively narrow. Thus,
only in the case of 2d growth can one get (ii) a wide dis-
tribution for the overall incubation time, with a width
comparable to the mean. Thus assuming (i)-(ii) to re-
sult entirely from the growth processes discussed here,
strongly points to a 2d (or 3d) morphology as controlling
the incubation times.
The early growth morphology clearly deserves further
experimental attention [31,34]. Typically, the in vitro
morphology of prion aggregates has been found to be fib-
rillar [35]. Frequently large fibrillar aggregates are also
observed post mortem in brain tissues. The morphology
and size scale for aggregates that cause neuronal death
and infection is not known. One could argue that the rea-
son why in vitro aggregates are not infectious is because
they do not have the proper morphology. We speculate
that the attachment to lipid membranes could make a
vital difference to the aggregation process, which is miss-
ing in in vitro experiments. It would be very interesting
to carry out the in vitro studies of prion aggregation in
presence of lipid membranes.
An important byproduct of our analysis is the ability to
predict the time course of infectivity from the DIC. Pro-
vided we take the doubling time (td) as an independent
experimental parameter, such predictions are very ro-
bust and do not rely on many details of the aggregation-
fissioning model, including initial growth morphologies.
Such predictions are particularly significant since exper-
iments which measure the time-course of infectivity, and
hence determine the lag phase, are extremely expensive
and time consuming. This dose dependence of the lag
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phase may well be a significant factor in assessing the
risk of infection.
Our results indicate that we can infer the (average)
time-course of infectivity using the information supplied
by the experimental DIC. Thus, based on our fits to the
experimental DIC, we have made testable predictions for
the time-course of infectivity, and in particular the lag
time, as a function of dose. These predictions are in
good agreement with the existing experimental results
and their further experimental validation would prove
very useful.
A factor which significantly affects the lag time is the
probablity of dimer attachment p; lowering p increases
the lag time. This is relevant in understanding the species
barrier effect in which there is a reduction of incubation
times with multiple passages in inter-species infection
[36]. During first passage, the attachment of dimers is
initially non-homologous but as the seed size increases it
should change to homologous attachment. Since the non-
homologous attachment probability should be smaller
[37], the lag phase should be longer for first passage as
compared to subsequent passages. Thus, in our picture,
most of the difference in incubation times should come
from the lag phase and the exponential growth phase
should be similar between first and second passages. This
has been observed experimentally for hamster scrapie
passaged in mice [13]. We note that the estimated dimer
attachment rates for mice and hamsters range from 9-60
per year (c.f. Table I), while for humans and cattle they
are maximally 0.6 per year.
Furthermore, we observe that the estimated aggregate
sizes are comparable between large animals (humans and
cattle) and small animals, all in the ballpark of tens of
nm, which is precisely the estimated size of the lipid
rafts on which prions are hypothesized to rest [42]. The
comparable sizes of aggregates at fission we find in our
model between small and large mammals strongly sug-
gests that the primary determinant of lag time is the
dimer attachment rate which is regulated primarily by
the concentration (for a given strain). This leads us to
speculate that the concentration of normal prion proteins
must vary dramatically between large and small species,
which naturally leads us to envision a link to metabolic
rate. Such a link is plausible if prion proteins play a func-
tional role in relieving oxidative stress as has been pro-
posed elsewhere [43]. The hypothesis of enhanced home-
ostatic PrPc concentration in small animals relative to
large ones is testable by direct examination of the brains
of uninfected animals.
Finally, as noted in the preceding section, our model
analysis yields 12 years as an extreme upper bound on
the vCJD incubation time. We actually get reasonable
doubling times only when we assume a total incubation
below 9 years, which is the lowest epidemiological esti-
mates. The important suggestion from this analysis is
that the vCJD cumulative infection toll is likely to be
several hundred, vs. several hundred thousand [32].
Acknowledgements. We acknowledge useful discussions
with F. Cohen. We thank D.D. Cox for a critical read-
ing and discussion of our fit to the Queniborough data.
R.V.K. and D.L.C. acknowledge support from the U.S.
Department of Energy, Office of Basic Energy Sciences,
Division of Materials Research. A.S. is supported by
Sandia which is a multiprogram laboratory operated by
Sandia Corporation, a Lockheed Martin company, for the
United States Department of Energy under Contract No.
DE-AC04-94AL85000. R.R.P.S. and D.L.C. have bene-
fitted from discussions at workshops of the Institute for
Complex Adaptive Matter. We are grateful for a grant
of supercomputer time from the Lawrence Livermore Na-
tional Laboratory.
[1] Prusiner, S.B., Gajdusek, D.C. and Alpers, M.P. Ann.
Neurol. 12, 1-9
[2] Prusiner, S.B., Cochran, S.P., Groth, D.F., Downey,
D.E., Bowman, K.A. & Martinez H.M. Ann. Neurol. 11,
353-358
[3] Prusiner, S.B., Tremblay, P., Safar, J., Torchia, M. &
DeArmond, S.J. (1999), in Prion Biology and Diseases,
ed. S.B. Prusiner (Cold Spring Harbor Laboratory Press,
Cold Spring Harbor NY, 1999), p. 113-145
[4] Dickinson, A.G. & Outram, G.W. (1979), in Slow trans-
missible diseases of the nervous system, ed. S.B. Prusiner
& W.J. Hadlow (Academic Press, New York, 1979), Vol.
2, p. 13-32.
[5] Manuelidis, L. & Fritch, W. (1996) Virology 215, 46-59
[6] Bolton, D. C. (1998) J. Gen. Virol. 79 2557-2562
[7] Beekes, M., Baldauf. E. & Diringer H. (1996) J. Gen.
Vir. 77, 1925-1930
[8] Kimberlin, R.H. &Walker C.A. (1988) in Novel infectious
agents and the central nervous system Wiley, Chichester
(Ciba Foundation Symposium 135), p. 37-62
[9] Mclean, A.R. & Bostock, C.J. Phil. Trans. R. Soc. Lond.
B (2000) 355, 1043-1050
[10] Stekel, D.J., Nowak, M.A. & Southwood, T.R.E. (1996)
Nature (London) 381, 119-119
[11] Anderson, R.M., et al. (1996) Nature, 382, 779-788.
[12] Kimberlin, R.H. & Walker, C. A. (1977) J. Gen. Virol.
34, 295-304
[13] Kimberlin, R.H. & Walker C.A. (1978) J. Gen. Virol. 42,
107-117
[14] Post, K., Brown D.R., Groschup, M., Kretzschmar, H.A.
& Riesner, D. (2000) Arch. Virol. (Suppl.) 16, S265-S273
[15] Eigen, M. (1996) Biophys. Chem. 63, A1-A18.
[16] Nowak, M.A., Krakauer, D.C., Klug, A. & May R.M.
(1998) Integr. Biol. 1, 3-15.
[17] Masel, J., Jansen V.A.A. & Nowak M.A. (1999) Biophys.
Chem. 77, 139-152.
[18] Masel J. & Jansen V.A.A. (2000) Biophys. Chem. 88,
47-59.
9
[19] Payne R.J.H. & Krakauer D.C. (1998) Proc. Roy. Soc.
Lond. B. 265, 2341-2346.
[20] Stumpf M.P.H. & Krakauer D.C. (2000) Proc. Nat. Acad.
Sc. USA 97, 10573-10577.
[21] Kellershohn N. & Laurent M. (2001) Biophys. Jour. 81
2517-2529.
[22] Prusiner, S.B., Groth, D.F., Cochran, S.P., Masiarz,
F.R., McKinley, M.P., Martinez, H.M. (1980) Biochem-
istry 19 4883-4891.
[23] Harper, J.D. & Lansbury Jr., P.T. (1997) Ann. Rev.
Biochem. 66, 385-407
[24] Slepoy, A., Singh, R.R.P., Pazmandi, F., Kulkarni, R. V.
& Cox, D.L. (2001) Phys. Rev. Lett. 87, 058101
[25] Cohen, F.E. & Prusiner, S.B. (1998) Ann. Rev. Biochem.
67 793-819
[26] Wille, H., Michelitsch, M.D., Guenebaut, V., Supat-
tapone, S., Serban A., Cohen, F.E., Agard, D.A. &
Prusiner, S.B. (2002) Proc. Nat. Acad. Sc. USA 99, 3563-
3568.
[27] Szabo, A. (1988) J. Mol. Biol. 199, 539-542
[28] Kimberlin, R.H. & Walker C.A. (1986) J. Gen. Virol. 67,
255-263.
[29] Taylor, D. M., McConnell, I. & Ferguson, C. E. (2000)
Jour. of Virol. Meth. 86 35-40
[30] Prusiner, S.B., Scott M., Foster D., Pan K.-M., Groth D.,
Mirenda C.,Torchia M.,Yang S.-L., Serban D., Carlson
G.A., Hoppe P.C., Westaway D., and DeArmond S.J.
(1990) Cell 63, 673-686
[31] Horiuchi, M. & Caughey, B. (1999) Structure with Fold-
ing and Design 7, R231-R240.
[32] Ghani, A.C., Ferguson, N.M., Donnelly, C.M., Anderson,
R.M., (2001) Nature406, 583-584; Valleron, A.-J., Boelle,
P.-Y., Will, R., Cesbron, J.-Y. (2001) Science 294,1726-
1728; Huillard d’Aignaux, J.N., Cousens, S.N., Smith,
P.G. (2001) Science 294, 1729-1731.
[33] Ferguson, N.M., Donnelly, C.M., Woolhouse, M.E.J., An-
derson, R.M. (1998) Phil. Trans. Ser. B R. Soc. Lon-
don352, 803-838.
[34] Rochet, J.C. & Lansbury P.T. (2000) Curr. Op. Struc.
Biol. 10, 60-68
[35] Ionescu-Zanetti, C., Khurana, R., Gillespie, J.R., Pet-
rick, J.S, Trabachino, L.C., Minert, L.J., Carter, S.A. &
Fink A.L. (1999) Proc. Nat. Acad. Sc. USA 96, 13175-
13179.
[36] Lasme´zas, C.I., Deslys, J.-P., Robain, O., Jaegly, A.,
Beringue, V., Peyrin, J.-M., Fournier, J.-G., Hauw, J.-J.,
Rossier J. & Dormont D. (1997) Science 275, 402-404.
[37] Horiuchi, M., Priola, S.A., Chabry, J. & Caughey, B.
(2000) Proc. Natl. Acad. Sci. USA 97, 5836-5841
[38] Lang, C.J.G., Heckmann, J.G., Neundo¨rfer, (1998) J.
Neurol. Sci. 160 128-139.
[39] The five deaths were: August 1998, October 1998 (2),
May 2000, October 2000, and from the scientific and jour-
nalistic literature we have inferred that the observed on-
set dates were: August 1996, September 1997, October
1997, and Jan 1999 (2). There is a four month uncer-
tainty about one of the latter onset times. For a report,
see
http://www.leics-ha.org.uk/cjd.htm and
http://www.rense.com/general4/cluster.htm.
[40] Stecklow, S., (June 12, 2001) Wall St. Journal p. A1.
[41] Allroggen, H., Dennis, G., Abbott, R.J., Pye, I.F., (2000)
J. Neurol. Neurosurg. Psychiatry 68, 375-378.
[42] Simons, K., Toomre, D. (2000) Nature Reviews Mol. Cell
Biol.1, 31-39.
[43] Guentchev, M., Siedlak, S.L., Jarius, C., Tagliavini, F.,
Castellani, R.J., Perry, G., Smith, M.A., Budka, H.
(2002) Neurobiology of Disease 9, 275-281; Milhavet, O.,
Lehmann, S. (2002), Brain Res. Rev. 38, 328-339; Brown,
D.R. (2001), Trends. Neurosci. 24, 85-90.
FIG. 1. Morphologies of seeds(bold Bs) and corresponding
aggregates due to the different rules: (A) qc = 3, (B) qc = 2,
(C) qc = 1 and (D) fibril growth (see text)
100 10000 1e+06 1e+08 1e+10
t
0
0.2
0.4
0.6
0.8
1
P1
(t)
0 2e+05 4e+05 6e+05 8e+05 1e+06t
0
1e−06
2e−06
3e−06
4e−06
5e−06
6e−06
P1
(t)
simulation data
analytic fit
(a) (b) (c) (d)
(A)
(B)
FIG. 2. (A) Comparison of simulation data for single seed
aggregation(Ai= 10, A= 80, c = 0.2%) and fit using ana-
lytical calculations (see text) for 2d growth with qc=3. The
unit of time is 1 simulation sweep. (B) Probability distribu-
tions for (a) qc = 1, (b) qc=2, (c) qc=3 and (d) sporadic with
qc=3 at the same concentration (c = 0.2%). The maximum
probability for all distributions is scaled to unity. The spo-
radic result is obtained by scaling the data at c = 1% with an
empirically determined c−3 factor.
10
0 1000 2000 3000 4000 5000
 A
0
0.2
0.4
0.6
0.8
1
t 2
(1)
/t m
(1)
c=0.0002%
c=0.002%
c=0.02%
c=0.2%
FIG. 3. Ratio of characteristic doubling time (t2) to mean
incubation time (tm) as a function of fissioning size A for
single seed growth in 2d for different monomer concentrations,
showing asymptotic compression as c → 0.
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FIG. 4. (A) Experimental and theoretical dose-incubation
curves for the 263K hamster scrapie strain for ri = 0. The
x-axis shows the incubation time and the y-axis shows the
logarithm of the number of seeds inoculated. The theoretical
curve is the best fit to the experimental data using the 2d
growth model for aggregation. (B) Same as A but for the
Sc237 strain in hamsters with ri = 88 (C) Same as A but for
the Me7 strain in C57Bl mice with ri = 88
TABLE I. Calculated best-fit parameters and predictions
for low dose lag times for 3 scrapie strains. a Ref. 28. b Ref.
3. c Ref. 29.
Strain t2 ri Lag time p
′
A S2
(days) (days) (days−1)
263K 3.9a 0 27.7 0.025 16 0.07
88 4.3 0.16 16 1.14
Sc237 2.1b 88 56.9 0.052 140 0.11
99 48.9 0.052 80 0.11
Me7 4.5c 88 107 0.033 360 3.86
99 89.6 0.033 140 3.75
TABLE II. Fits to incubation time distribution for BSE
(Refs.[11,33] ).
l n p′ tm t2
(yrs−1) (yrs.) (days)
2 6 0.57 2.8 20
2 23 0.61 4.5 5
10 6 0.15 3.2 16
TABLE III. Fits to onset time distribution from Queni-
borough cluster (refs. 39-41). Here l = 1 + p/p′. Doubling
times are computed for best fit tm, values, and the upper and
lower quotes for p′, tm, σ represent 95% confidence intervals.
t2 values are only quoted for best fit p
′.
l n p′ tm(t
(+)
m , t
(−)
m ) σ(σ
(−), σ(+)) t2
(yrs−1) (yrs) (yrs) (days)
2 4 0.55(0.21,0.89) 2.3(1.4,5.4) 1.2(0.8,3.2) 61
2 20 0.64(0.25,1.07) 4.1(2.5,10.6) 1.2(0.7,3.1) 45
10 6 0.17(0.27,0.067) 2.9(1.8,7.3) 1.2(0.7,3.1) 56
10 10 0.20(0.077,0.32) 3.6(2.2,9.3) 1.2(0.7,3.1) 37
11
